Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis

被引：0

作者：

Knowles, Susan ^{[1
]}

Taroumian, Sara ^{[1
]}

Lisse, Jeffrey R. ^{[1
]}

Yanes, James ^{[1
]}

Ampel, Neil M. ^{[2
]}

Gall, Eric P. ^{[3
]}

Grau, Rafael G. ^{[1
]}

Bode, Barbara Y. ^{[2
]}

Vaz, Berchman A. ^{[4
]}

Galgiani, John ^{[5
]}

Hoover, Susan E. ^{[1
]}

机构：

[1] Univ Arizona, Tucson, AZ USA

[2] So AZ VA Med Ctr, Tucson, AZ USA

[3] Arizona Arthrit Ctr, Tucson, AZ USA

[4] Catalina Pointe Arthrit & Rheumatol, Tucson, AZ USA

[5] Valley Fever Ctr Excellence, Tucson, AZ USA

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2466

引用

页码：S961 / S961

页数：1

共 50 条

[1] Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs
Taroumian, Sara
Knowles, Susan L.
Lisse, Jeffrey R.
Yanes, James
Ampel, Neil M.
Vaz, Austin
Galgiani, John N.
Hoover, Susan E.
ARTHRITIS CARE & RESEARCH, 2012, 64 (12) : 1903 - 1909
[2] An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Knowles, Susan
Sudano, Dominick
Taroumian, Sara
Ampel, Neil M.
Galgiani, John
Lisse, Jeffrey R.
Hoover, Susan E.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S919 - S919
[3] Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis
Ajaz, Usman
Ampel, Neil M.
Bhalla, Varun
Lisse, Jeffrey R.
Sudano, Dominick
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Sudano, Dominick
Kwoh, C. Kent
Zhou, Lili
Ashbeck, Erin L.
Lo-Ciganic, Wei-Hsuan
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[5] Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
R Fleischmann
Arthritis Res Ther, 5
[6] Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
Fleischmann, R
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S3 - S3
[7] Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review
van der Velde, Gabrielle
Pham, Ba'
Machado, Marcio
Ieraci, Luciano
Witteman, William
Bombardier, Claire
Krahn, Murray
ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 65 - 78
[8] Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases
Fazaa, Alia
Makhlouf, Yasmine
Ben Ouhiba, Amad
Miladi, Saoussen
Sellami, Mariem
Ouenniche, Kmar
Souabni, Leila
Kassab, Salma
Chekili, Selma
Zakraoui, Leith
Ben Abdelghani, Kawther
Laatar, Ahmed
THERAPIE, 2021, 76 (05): : 467 - 474
[9] What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs?
Martins, Ana
Oliveira, Daniela
Rocha, Teresa Martins
Bernardo, Alexandra
Costa, Lucia
Pimenta, Sofia
Bernardes, Miguel
CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 251 - 258
[10] What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs?
Ana Martins
Daniela Oliveira
Rafaela Nicolau
Teresa Martins Rocha
Alexandra Bernardo
Lúcia Costa
Sofia Pimenta
Miguel Bernardes
Clinical Rheumatology, 2024, 43 : 251 - 258

← 1 2 3 4 5 →